Table 1.
Characters of included studies in the meta-analysis.
| Reference | Number of Patients(High/Low TMB) | Area | Type of ICIs | dMMR/MSI | Sample Source | Sequencing Method | TMB Cutoff | Median TMB (Range) | Outcome | Score of NOS |
|---|---|---|---|---|---|---|---|---|---|---|
| Chen et al. 2020 (1, 24) | 115(21/94) | Western | Anti-CTLA-4 and anti-PD-L1 | 0 | Blood | NGS (GuardantOMNI) |
28muts/Mb | 15.3muts/Mb (0.96-85.4) |
OS | 7 |
| Le et al. 2015 (1, 28) | 15(NA) | Multiple areas | Anti-PD-1 | 60.0% | Tumor | WES | NA | 771muts (5-4025) |
OS | 7 |
| Lee et al. 2020 (1, 29) | 63(NA) | western | Immune checkpoint inhibitors | NA | Tumor | NGS (MSK-IMPACT) |
13.17muts/Mb | 7.9muts/Mb (NA) | OS | 7 |
| Li et al. 2020 (1, 30) | 403(NA) | Multiple areas | Immune checkpoint inhibitors | NA | Tumor | NA | NA | NA | OS | 7 |
| Lin et al. 2020 (1, 31) | 109 (39/70) |
western | Immune checkpoint inhibitors | NA | Tumor | NGS (MSK-IMPACT) |
11muts/Mb | NA | OS | 7 |
| Peng et al. 2021 (1, 32) | 398(NA) | western | Immune checkpoint inhibitors | NA | Tumor | NA | NA | 9.95muts/Mb (0.05-188.32) |
OS | 7 |
| Samstein et al. 2019 (1, 9) | 110(22/88) | western | Immune checkpoint inhibitors | NA | Tumor | NGS (MSK-IMPACT) |
52.2muts/Mb | 7.90muts/Mb (0-203.64) |
OS | 8 |
| Schrock et al. 2019 (1, 19) | 22(13/9) | western | Anti-PD-1/L1 | 100% | Tumor | NGS | 37-41muts/Mb | 47.5muts/Mb (13-91) |
ORR | 7 |
| Song et al. 2020 (1, 33) | 109(87/22) | Multiple areas | Anti-PD-1/L1 | NA | Tumor | NGS (MSK-IMPACT) |
52.66muts/Mb | NA | OS | 9 |
| Valero et al. 2021 (1, 34) | 50(43/7) | western | Anti-PD-1/L1 | NA | Tumor | NGS (MSK-IMPACT) |
10muts/Mb | NA | ORR | 9 |
| Yarchoan et al. 2019 (1, 35) | 1141 (89/1052) | western | Anti-PD-1/L1 | 4.7% | Tumor | NGS (FoundationOne) |
10muts/Mb | TMB-H:48.285 TMB-L:3.48 |
ORR | 7 |
| Zaidi et al. 2020 (1, 36) | 2083(392/1691) | Multiple areas | Immune checkpoint inhibitors | 14.7% | Tumor | NGS (AmpliSeq panel) |
17muts/Mb | NA | OS | 7 |
| Zhou et al. 2021 (1, 37) | 396(198/198) | Multiple areas | Immune checkpoint inhibitors | 21% | Tumor | NA | 96muts | 96muts | OS | 9 |
TMB, tumor mutational burden; ICIs, immune checkpoint inhibitors; CTLA-4, cytotoxic T lymphocyte-associated antigen 4; PD-L1, programmed death-ligand 1; PD-1, programmed cell death protein 1; dMMR, deficient mismatch repair; microsatellite instability, MSI; NGS, next-generation sequencing; WES, whole-exome sequencing; muts/Mb, mutations per megabase; muts mutations; OS, overall survival; ORR, objective response rate/overall response rate; NOS, Newcastle-Ottawa Scale; NA, not available.